menu
    • menu
    [{"orgOrder":0,"company":"HistoIndex","sponsor":"Galecto","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"PAT-1251","moa":"Lysyl oxidase homolog 2","graph1":"Oncology","graph2":"Phase II","graph3":"HistoIndex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HistoIndex \/ Galecto","highestDevelopmentStatusID":"8","companyTruncated":"HistoIndex \/ Galecto"},{"orgOrder":0,"company":"Galecto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"PAT-1251","moa":"Lysyl oxidase homolog 2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galecto \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Galecto \/ Undisclosed"},{"orgOrder":0,"company":"Galecto","sponsor":"Pharmakea therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Partnership","leadProduct":"PAT-1251","moa":"Lysyl oxidase homolog 2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galecto \/ Pharmakea therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ Pharmakea therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals for PAT-1251

    Menu

    PAT-1251

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            HistoIndex

                            Singapore arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            HistoIndex

                            Singapore arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PAT-1251

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Galecto

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            HistoIndex and Galecto to Collaborate on Galecto's Phase 2a MYLOX-1 Clinical Trial to Advance Myelofibrosis As...

                            Details : AI-based Stain-free imaging technology will be utilized to analyze and quantify collagen-associated parameters as part of Galecto's Phase 2a trial for its oral LOXL2 inhibitor GB2064 in myelofibrosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 20, 2021

                            Lead Product(s) : PAT-1251

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Galecto

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Galecto

                            Denmark arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Galecto

                            Denmark arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PAT-1251

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase II

                            Sponsor : Pharmakea therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Galecto to merge with onetime Celgene partner PharmAkea

                            Details : The two firms will combine & put in robust fibrosis and cancer services, including a recently inhaled galectin-3 modulator ph IIb for the potential treatment of idiopathic pulmonary fibrosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 07, 2020

                            Lead Product(s) : PAT-1251

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase II

                            Sponsor : Pharmakea therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Galecto

                            Denmark arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Galecto

                            Denmark arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PAT-1251

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of PAT-1251 in Healthy Adult Subjects

                            Details : PAT-1251 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 02, 2016

                            Lead Product(s) : PAT-1251

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth